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National Center for Pharmaceutical Crops 
Arthur Temple College of Forestry and Agriculture 
Stephen F. Austin State University 
Nacogdoches, TX  75962, USA 
WHY PHARMACEUTICAL CROPS?  
1.  Plants Save Lives 
•  Medicinal plants have been and will continue to be the primary solution for human diseases. 
>75% of the world populations continue to rely on traditional plant medicines. 
•  Approximately 40-50% of all currently used drugs have an origin in natural products. 
•  Cancer is the biggest killer of Americans and causes one out of every four deaths in the U.S. 
Approximately 65% of FDA-approved cancer drugs are derived from plants.  
•  Infectious diseases cost the U.S. economy at least $20 billion per year. Approximately 75% 
of FDA-approved anti-infective drugs are of natural origin.  
2.  Security of U.S. Strategic Pharmaceuticals 
•  Plant-based pharmaceuticals generate $30 billion in annual sales.    
•  Many plant-derived pharmaceuticals have complex structures that cannot be commercially 
synthesized. 
•  Current supplies of many critical pharmaceuticals rely on natural resources. 
•  Due to a lack of sustainable use and conservation, genetic biodiversity of medicinal plants is 
continuously under the threat of extinction. 
•  The U.S. depends on other countries for many valuable pharmaceuticals, but these foreign 
supplies are uncertain.  
•  U.S. research is critically limited in development and use of crops for pharmaceutical 
production although U.S. agriculture is well  developed for economical mass production of 
food and fiber crops. 
•  U.S. farmers urgently need high added-value alternative crops.  
•  Bioprospecting becomes imperative: at least 1/4 of the flora will be extinct in the next 50 
years while only <1% of the world’s flora (>310,000 species) has been extensively 
investigated for medicinal uses.   
CURRENT KEY INVESTIGATORS 
Shiyou Li, Ph.D., Director and Research Professor 
Dr. Li has 26 years of research experience in medicinal plants specializing in the development of 
new pharmaceutical crops and strategies for induced production of targeted natural compounds. 
He is the author or co-author of four books and 65 peer-reviewed articles. He has established 
research collaboration with over 20  institutions. Dr. Li is also author of 10 new plant species/
varieties and inventor of 6 high-yielding pharmaceutical crop cultivars. He discovered “induced 
endogenous autotoxicity” in plants and developed novel “Trichome Management” techniques to 
induce production and diversity of target secondary metabolites in pharmaceutical crops (patent 
issued). He is the founding editor-in-chief of the peer-review journal Pharmaceutical Crops.   
Ping Wang, Ph.D., Research Scientist  
Dr. Wang has isolated and identified 120 compounds from medicinal plants including six new 
compound and is the author of 21 peer-reviewed articles. She is a co-inventor on one U.S. patent 
application. 
Wei Yuan, Ph.D., Research Scientist  
Dr. Yuan has 10 years of experience in natural products chemistry. He has isolated and identified 
over 100 compounds from plants and fungi including 40 new compounds. He is the author of 23 
peer-reviewed articles and is a co-inventor on one U.S. patent application.  
Zushang Su, Ph.D., Research Associate 
Dr. Su has several years of research experience in natural products chemistry and ethnobotany. 
 
Collaborators: Dr. Bharat B. Aggarwal (M.D. Anderson  Cancer Center), Dr. David Creech (SFA 
Gardens), Dr. Jason Fritzler (SFA Dept of Biology), and Dr. Josephine Taylor (SFA Dept of 
Biology). 
FACILITIES 
 
Laboratories:  The Center has a 3,000 ft2 analytical lab, a 3,500 ft2 pilot production facility for large-scale 
extractions, a NMR lab (with Department of Chemistry), and a 2,500 ft2 greenhouse for plant propagation, 
germplasm preservation, and development.  
 
Experimental Sites and Garden:  The Center has two experimental field sites and is constructing a Medicinal 
Fern Garden at SFA in collaboration with the SFA Mast Arboretum and the Pineywoods Native Plant Center.  
SFA is a pioneer in pharmaceutical crop research in the United States.  The 
National Center for Pharmaceutical Crops (NCPC) was established in 2004 
through U.S. Congressional Appropriations with the effort of U.S. Senator 
Kay Bailey Hutchison.  The Center has received great supports from 
Senator Hutchison, Congressman Louie Gohmert, SFA Administration, 
and local communities in the last several years. 
MAJOR SPONSORS 
U.S. Centers for Disease Control and Prevention                         Stephen F. Austin State University 
U.S. Department of Agriculture                                                  Houston Livestock Show & Rodeo 
U.S. Department of Education                                                  The Fondren Foundation 
Camptotech, Inc.                                                                              Phoenix Biotechnology, Inc. 
Private Donations: Mr. and Mrs D. Dolben, Mr. C. Poland, Mr. J. Hicks   
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  New High-value Crops      Improved Human Health 
Novel Anti-cancer & Antiviral Agents 
Dr. Ping Wang, Dr. Wei Yuan, Dr. Zushang Su, and Dr. Shiyou Li 
 
ACHIEVEMENTS 
 
1. Security of National Strategic Pharmaceuticals:  
 Anti-cancer Camptothecins: Since1993, SFA scientists have been conducting extensive 
research on Camptotheca, the major source of promising anti-cancer camptothecin drugs. Results 
include the development of high-yield cultivars and patented techniques that further increase 
camptothecin yields by 20-fold and that can be widely applied to many medicinal plants. 
 Production of Shikimic Acid from Native Plants: Recently, SFA has discovered the leaves of 
sweetgum (Liquidambar styraciflua) as a new source of shikimic acid, the bottleneck material 
for producing the anti-influenza drug Tamiflu®. With our technology, current natural resources 
in East Texas alone would produce a sufficient quantity of shikimic acid to meet the global 
Tamiflu® demand (patent allowed).   
2. Identification of Novel Bioactive Agents:  To date, over 1,200 species of vascular plants 
representing 138 families found in Texas have been collected and screening for bioactivities. 
Over 750 compounds, including 115 new compounds, have been successfully isolated and 
identified from 36 species of native plants such as buttonbush (Cephalanthus occidentalis) and 
buckeye (Aesculus pavia), the promising exotic Camptotheca, and invasive species (Salvinia 
molesta). 
 Anti-cancer Compounds:  Through cytotoxicity assays and DNA Topoisomerase I & II activity 
screenings, six novel anti-tumor compounds have been identified. 
 Antiviral Compounds: In cooperation with the National Institute of Allergy and Infectious 
Diseases (NIAID) and Camptotech, Inc., 24 new compounds have been screened for respiratory, 
herpes, hepatitis C, West Nile, and Yellow Fever viruses. The projects entitled, “Identification of 
Antiviral Agents from Plants” funded by the U.S. Centers for Disease Control and Prevention 
(CDC) and “Identification of antiviral compounds from native pteridophytes (ferns) of North 
America” funded by SFA are currently underway. 
 Antifungal Compounds: We have found that trifolin, hyperoside, and camptothecin have potent 
antifungal activity against Fusarium and other important agricultural pathogens (patent pending). 
MISSION 
The mission of the National Center for Pharmaceutical Crops is to develop crops for 
the production of pharmaceutical and other bioactive compounds. The Center is the 
only one of its kind in the U.S. and seeks to: 
v Improve human health by discovering novel anti-tumor and antiviral agents from 
native and invasive plant species 
v Revitalize the U.S. and Texas rural economy by developing high-value 
pharmaceutical crops  
v Enhance U.S. security in strategic pharmaceuticals, by reducing dependency and 
vulnerability on foreign supply of active pharmaceutical ingredients . 
